Natco Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on July 23, 2025.
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.7 pts less than Nifty Smallcap 250 and 3.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Natco Pharma's board, on July 23, 2025, approved acquiring 51,643,319 shares (35.75% stake) in South African pharmaceutical company Adcock Ingram Holdings at ZAR 75 per share, totaling around ₹2,000 crores including transaction costs. The offer values Adcock Ingram at about ZAR 11 billion (US$632 million), and Adcock will be delisted from the JSE post-transaction, with Bidvest holding 64.25% and Natco 35.75%. Adcock Ingram reported FY24 revenue of ZAR 9,643 million (~US$536 million) and net profit of R814 million. Separately, the board approved incorporating a wholly owned subsidiary in South Africa (Natco Pharma South Africa Proprietary Limited) with investment up to ₹2,100 crores, and the liquidation of Time Cap Overseas Limited, a wholly owned step-down holding subsidiary for Brazil operations. The deal is expected to close by December 31, 2025, subject to regulatory approvals.
This is a major strategic international expansion for Natco, committing roughly ₹2,000 crores to enter the South African pharma market, which could diversify revenue and open an Africa gateway but also exposes shareholders to execution, regulatory, and currency risks. The stock may see a positive reaction given the size of the deal, though the cash outflow is significant relative to Natco's scale.